Syndicate Bio, a genomics startup, has been launched by Abasi Ene-Obong, a former co-founder and CEO of the African genomics startup 54gene.
According to Abasi Ene-Obong’s LinkedIn profile, Syndicate Bio was co-launched with Jumi Popoola, who serves as the company’s chief scientific officer, and Estelle Dogbo, who serves as its chief operations officer. Syndicate Bio has been in stealth mode since March 2023.
Ene-Obong expressed excitement about the development, stating that Syndicate Bio will empower inclusive advancements in global genomics science. He claims that Syndicate Bio would spearhead genomics and precision medicine activities in the most varied parts of the world, beginning with Africa.
Ene-Obong resigned from his position as CEO of 54Gene last year. Speaking about it, he said: “I left the firm I established and cherished about a year ago. I made the decision not to add fuel to the rumors and quietly withdrew so that I could work on the broader objective.”
Ene-Obong was previously accused of financial impropriety, although the accusations have never been proven. His resignation’s cause was not made public. However, he left the genomics firm with YC backing just as it was having to deal with the difficulties of the recession, which resulted in layoffs.
Ene-Obong continued that the startup employs broad collaborations with governments, pharma companies, academia, and other stakeholders to promote local precision medicine impact and create potent datasets that can be used for drug discovery and development.
According to Ene-Obong, in the upcoming months, the startup will be discussing some of the significant advancements made in support of its vision and goal.
